Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain | Zendy

Hussein A. Tawbi | Zendy; Peter Forsyth | Zendy; Alain P. Algazi | Zendy; Omid Hamid | Zendy; F. Stephen Hodi | Zendy; Stergios J. Moschos | Zendy; Nikhil I. Khushalani | Zendy; Karl D. Lewis | Zendy; Christopher D. Lao | Zendy; Michael A. Postow | Zendy; Michael B. Atkins | Zendy; Marc S. Ernstoff | Zendy; David A. Reardon | Zendy; Igor Puzanov | Zendy; Ragini R. Kudchadkar | Zendy; Reena Thomas | Zendy; Ahmad A. Tarhini | Zendy; Anna C. Pavlick | Zendy; Joel Jiang | Zendy; Alexandre Avila | Zendy; Sheena Demelo | Zendy; Kim Margolin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Author(s) -

Hussein A. Tawbi,

Peter Forsyth,

Alain P. Algazi,

Omid Hamid,

F. Stephen Hodi,

Stergios J. Moschos,

Nikhil I. Khushalani,

Karl D. Lewis,

Christopher D. Lao,

Michael A. Postow,

Michael B. Atkins,

Marc S. Ernstoff,

David A. Reardon,

Igor Puzanov,

Ragini R. Kudchadkar,

Reena Thomas,

Ahmad A. Tarhini,

Anna C. Pavlick,

Joel Jiang,

Alexandre Avila,

Sheena Demelo,

Kim Margolin

Publication year - 2018

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1805453

Subject(s) - ipilimumab , nivolumab , medicine , melanoma , metastatic melanoma , oncology , brain metastasis , metastasis , immunotherapy , cancer , cancer research

Brain metastases are a common cause of disabling neurologic complications and death in patients with metastatic melanoma. Previous studies of nivolumab combined with ipilimumab in metastatic melanoma have excluded patients with untreated brain metastases. We evaluated the efficacy and safety of nivolumab plus ipilimumab in patients with melanoma who had untreated brain metastases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research